Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

被引：0
|
作者：
Lennart Tonneijck
Mark M. Smits
Marcel H. A. Muskiet
Trynke Hoekstra
Mark H. H. Kramer
A. H. Jan Danser
Michaela Diamant
Jaap A. Joles
Daniël H. van Raalte
机构：
[1] VU University Medical Center Amsterdam,Department of Internal Medicine/Diabetes Center
[2] VU University Amsterdam,Department of Health Sciences and the EMGO Institute for Health and Care Research
[3] VU University Medical Center,Department of Epidemiology and Biostatistics
[4] Erasmus University Medical Center,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[5] University Medical Center,Department of Nephrology and Hypertension
来源：
Diabetologia | 2016年 / 59卷
关键词：
Diabetes; Exenatide; Glomerular filtration rate; Glomerular hyperfiltration; GLP-1 receptor agonist; Glucagon-like peptide-1; Renal function; Renal haemodynamics; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1412 / 1421
页数：9
相关论文
共 50 条
  • [41] Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
    Briones, Mariele
    Bajaj, Mandeep
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (08) : 1055 - 1064
  • [42] Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
    Athauda, Dilan
    Maclagan, Kate
    Skene, Simon S.
    Bajwa-Joseph, Martha
    Letchford, Dawn
    Chowdhury, Kashfia
    Hibbert, Steve
    Budnik, Natalia
    Zampedri, Luca
    Dickson, John
    Li, Yazhou
    Aviles-Olmos, Iciar
    Warner, Thomas T.
    Limousin, Patricia
    Lees, Andrew J.
    Greig, Nigel H.
    Tebbs, Susan
    Foltynie, Thomas
    LANCET, 2017, 390 (10103): : 1664 - 1675
  • [43] Canakinumab in patients with COVID-19 and type 2 diabetes-A multicentre, randomised, double-blind, placebo-controlled trial
    Hepprich, Matthias
    Mudry, Jonathan M.
    Gregoriano, Claudia
    Jornayvaz, Francois R.
    Carballo, Sebastian
    Wojtusciszyn, Anne
    Bart, Pierre-Alexandre
    Chiche, Jean-Daniel
    Fischli, Stefan
    Baumgartner, Thomas
    Cavelti-Weder, Claudia
    Braun, Dominique L.
    Gunthard, Huldrych F.
    Beuschlein, Felix
    Conen, Anna
    West, Emily
    Isenring, Egon
    Zechmann, Stefan
    Bucklar, Gabriela
    Aubry, Yoann
    Dey, Ludovic
    Mueller, Beat
    Hunziker, Patrick
    Schutz, Philipp
    Cattaneo, Marco
    Donath, Marc Y.
    ECLINICALMEDICINE, 2022, 53
  • [44] Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
    Dejgaard, Thomas Fremming
    Frandsen, Christian Seerup
    Hansen, Tanja Stenbaek
    Almdal, Thomas
    Urhammer, Soren
    Pedersen-Bjergaard, Ulrik
    Jensen, Tonny
    Jensen, Andreas Kryger
    Holst, Jens Juul
    Tarnow, Lise
    Knop, Filip Krag
    Madsbad, Sten
    Andersen, Henrik Ullits
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03): : 221 - 232
  • [45] The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial
    Perrin, Nina E. S. S.
    Jaremko, Georg A.
    Berg, Ulla B.
    PEDIATRIC NEPHROLOGY, 2008, 23 (06) : 947 - 954
  • [46] The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial
    Nina E. S. S. Perrin
    Georg A. Jaremko
    Ulla B. Berg
    Pediatric Nephrology, 2008, 23 : 947 - 954
  • [47] Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Gitelman, Stephen E.
    Bundy, Brian N.
    Ferrannini, Ele
    Lim, Noha
    Blanchfield, J. Lori
    DiMeglio, Linda A.
    Felner, Eric, I
    Gaglia, Jason L.
    Gottlieb, Peter A.
    Long, S. Alice
    Mari, Andrea
    Mirmira, Raghavendra G.
    Raskin, Philip
    Sanda, Srinath
    Tsalikian, Eva
    Wentworth, John M.
    Willi, Steven M.
    Krischer, Jeffrey P.
    Bluestone, Jeffrey A.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (08): : 502 - 514
  • [48] A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes
    Nwosu, Benjamin Udoka
    Maranda, Louise
    Cullen, Karen
    Greenman, Lisa
    Fleshman, Jody
    McShea, Nancy
    Barton, Bruce A.
    Lee, Mary M.
    PLOS ONE, 2015, 10 (09):
  • [49] The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
    Laurence Lion-François
    François Gueyffier
    Catherine Mercier
    Daniel Gérard
    Vania Herbillon
    Isabelle Kemlin
    Diana Rodriguez
    Tiphanie Ginhoux
    Emeline Peyric
    Virginie Coutinho
    Valentine Bréant
    Vincent des Portes
    Stéphane Pinson
    Patrick Combemale
    Behrouz Kassaï
    Orphanet Journal of Rare Diseases, 9
  • [50] The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
    Lion-Francois, Laurence
    Gueyffier, Francois
    Mercier, Catherine
    Gerard, Daniel
    Herbillon, Vania
    Kemlin, Isabelle
    Rodriguez, Diana
    Ginhoux, Tiphanie
    Peyric, Emeline
    Coutinho, Virginie
    Breant, Valentine
    des Portes, Vincent
    Pinson, Stephane
    Combemale, Patrick
    Kassai, Behrouz
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9 : 142
12345